Molecular characterization of the A52 murine hepatocellular carcinoma cell line

Abstract

Background: To combat hepatocellular carcinoma (HCC) disease heterogeneity and growing mortality, there is an urgent need for targeted and personalized therapeutics. While syngeneic mouse models are commonly used for preclinical validation of these therapeutics, the lack of genetically characterized murine cell lines adds uncertainty to the study of drug-gene interactions in these models. We previously generated a novel murine cell line, A52, from a diethylnitrosamine (DEN)-induced adiponectin-knockout mouse model. Here, we present a comprehensive genomic and transcriptomic characterization of the A52 cell line.

Methods: A52 cells were grown in various culture medium compositions to investigate robustness to simple media. Whole-genome sequencing (WGS) and RNAseq were performed on A52 cells from both cell culture and syngeneic tumor tissue, as well as a reference cell line representing non-tumor cells, AML-12.

Results: A52 was found to show robust growth in all medium compositions. Substantial chromosomal instability was observed in A52, including trisomy 15 and notable amplifications of oncogenic loci such as Myc and Cd274 (PDL-1), alongside frequent small variants and structural rearrangements. Notably, the cell line harbors the common HCC driver Braf V584E mutation, and a novel Plk1 p.R364W variant predicted as a driver mutation. Transcriptomic profiling defined a distinct “A52 gene signature” enriched in EGFR-ERBB signaling and cell migration pathways. Integrative analyses demonstrated that the A52 gene signature aligns closely with a subset of human HCC lacking CTNNB1 mutations.

Conclusion: This study provides a critical genetic resource, facilitating more precise preclinical modeling and therapeutic validation in HCC.

Keywords

carcinoma / cell line / gene expression profiling / genomics / hepatocellular / mice

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] AIHW. Cancer in Australia 2019. AIHW; 2019.

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34.

[4] Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024; 31(8): 1105-1112.

[5] Sun H, Yang H, Mao Y. Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering. Front Pharmacol. 2023; 14:1150151.

[6] Xu MM, Pu Y, Zhang Y, Fu YX. The role of adaptive immunity in the efficacy of targeted Cancer therapies. Trends Immunol. 2016; 37(2): 141-153.

[7] Liu S, Huang F, Ru G, et al. Mouse models of hepatocellular carcinoma: classification, advancement, and application. Front Oncol. 2022; 12:902820.

[8] Zhuo Z, Hu J, Yang X, et al. Ailanthone inhibits Huh7 Cancer cell growth via cell cycle arrest and apoptosis in vitro and in vivo. Sci Rep. 2015; 5(1):16185.

[9] Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, et al. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology. 2012; 262(3): 834-845.

[10] Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019; 121(2): 101-108.

[11] Romualdo GR, Leroy K, Costa CJS, et al. In vivo and in vitro models of hepatocellular carcinoma: current strategies for translational modeling. Cancer. 2021; 13(21):5583.

[12] Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8(7): 731-737.

[13] Walker S, Wankell M, Ho V, et al. Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. PLoS One. 2019; 14(2):e0212860.

[14] McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9): 1297-1303.

[15] Diaz-Gay M, Vangara R, Barnes M, et al. Assigning mutational signatures to individual samples and individual somatic mutations with SigProfilerAssignment. bioRxiv 2023.

[16] Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinf (Oxf). 2016; 32(8): 1220-1222.

[17] Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021; 10(2):giab008.

[18] Sollner JF, Leparc G, Hildebrandt T, et al. An RNA-Seq atlas of gene expression in mouse and rat normal tissues. Sci Data. 2017; 4(1):170185.

[19] Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10): 1113-1120.

[20] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550.

[21] Gillman R, Field MA, Schmitz U, Hebbard L. TARGET-SL: precision essential gene prediction using driver prioritisation and synthetic lethality. Brief Bioinform. 2025; 26(3): 1-11.

[22] Hou JP, Ma J. DawnRank: discovering personalized driver genes in cancer. Genome Med. 2014; 6(7):56.

[23] He G, Yu GY, Temkin V, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010; 17(3): 286-297.

[24] Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18(11): 696-705.

[25] Damrauer JS, Smith MA, Walter V, et al. Genomic characterization of rare molecular subclasses of hepatocellular carcinoma. Commun Biol. 2021; 4(1):1150.

[26] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283): 899-905.

[27] Connor F, Rayner TF, Aitken SJ, et al. Mutational landscape of a chemically-induced mouse model of liver cancer. J Hepatol. 2018; 69(4): 840-850.

[28] He Z, Wilson A, Rich F, et al. Chromosomal instability and its effect on cell lines. Cancer Rep (Hoboken). 2023; 6(6):e1822.

[29] Kaufmann WK, Ririe DG, Kaufman DG. Phenobarbital-dependent proliferation of putative initiated rat hepatocytes. Carcinogenesis. 1988; 9(5): 779-782.

[30] Dewdney B, Alanazy M, Gillman R, et al. The effects of fructose and metabolic inhibition on hepatocellular carcinoma. Sci Rep. 2020; 10(1):16769.

[31] Ogawa K, Osanai M, Obata M, Ishizaki K, Kamiya K. Gain of chromosomes 15 and 19 is frequent in both mouse hepatocellular carcinoma cell lines and primary tumors, but loss of chromosomes 4 and 12 is detected only in the cell lines. Carcinogenesis. 1999; 20(11): 2083-2088.

[32] Zimonjic DB, Ullmannova-Benson V, Factor VM, Thorgeirsson SS, Popescu NC. Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease. Cancer Genet Cytogenet. 2009; 191(1): 17-26.

[33] Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983; 304(5927): 596-602.

[34] Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010; 2(1): 16-20.

[35] Girish V, Lakhani AA, Thompson SL, et al. Oncogene-like addiction to aneuploidy in human cancers. Science. 2023; 381(6660):eadg4521.

[36] Zimonjic DB, Zhang H, Shan Z, et al. DNA amplification associated with double minutes originating from chromosome 19 in mouse hepatocellular carcinoma. Cytogenet Cell Genet. 2001; 93(1–2): 114-116.

[37] Williams GM, Iatropoulos MJ, Wang CX, et al. Diethylnitrosamine exposure-responses for DNA damage, centrilobular cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit some non-linearities. Carcinogenesis. 1996; 17(10): 2253-2258.

[38] Matsumura S, Sato H, Otsubo Y, Tasaki J, Ikeda N, Morita O. Genome-wide somatic mutation analysis via Hawk-Seq reveals mutation profiles associated with chemical mutagens. Arch Toxicol. 2019; 93(9): 2689-2701.

[39] Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020; 578(7793): 94-101.

[40] Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015; 47(12): 1402-1407.

[41] Petljak M, Alexandrov LB, Brammeld JS, et al. Characterizing mutational signatures in human Cancer cell lines reveals episodic APOBEC mutagenesis. Cell. 2019; 176(6): 1282-1294.e20.

[42] Fang H, Zhu X, Yang H, Oh J, Barbour JA, Wong JWH. Deficiency of replication-independent DNA mismatch repair drives a 5-methylcytosine deamination mutational signature in cancer. Sci Adv. 2021; 7(45):eabg4398.

[43] Cordero C, Mehta KPM, Weaver TM, et al. Contributing factors to the oxidation-induced mutational landscape in human cells. Nat Commun. 2024; 15(1):10722.

[44] Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014; 15(1): 1-10.

[45] Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin Cancer Res. 2022; 28(21): 4618-4628.

[46] Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene. 2001; 20(53): 7812-7816.

[47] Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R. Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab Anim. 2015; 49(1 Suppl): 59-69.

[48] Mutoh S, Sobhany M, Moore R, et al. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci Signal. 2013; 6(274):ra31.

[49] Groll N, Petrikat T, Vetter S, et al. Inhibition of beta-catenin signaling by phenobarbital in hepatoma cells in vitro. Toxicology. 2016; 370: 94-105.

[50] Sun W, Su Q, Cao X, et al. High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma. Int J Genomics. 2014; 2014:312130.

[51] Zhang Y, Wang S, Xiao J, Zhou H. Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma. Biosci Rep. 2019; 39(2): 1-9.

[52] Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017; 32(1): 57-70.e3.

[53] Dantzer C, Dif L, Vache J, Basbous S, Billottet C, Moreau V. Specific features of beta-catenin-mutated hepatocellular carcinomas. Br J Cancer. 2024; 131(12): 1871-1880.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.